Aegean Marine Story...
Health Care: Drugs
Optimer Pharmaceuticals Inc. (OPTR: NASDAQ)
$13.18 -0.33 | -2.44%
02/08/12 - 04:00 PM ET
321.83K / 858.40K
Vol / Avg. Vol:13.51 / 13.51
Open / Prev. Close:13.09 - 13.51
Today's Range:6.81 - 17.95
52 Wk Range:7.68%
Performance YTD:TheStreet Rating:
Portfolios with OPTR
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorEarnings Short Squeeze Play...
- UserFrank
- Contributor10 Biotech Stocks on Clinic...
- UserPART 6 JPMorgan 28th Annual...
- ContributorBarron's Insider Purchases ...
- UserRocket Stocks for the week ...
- User5MONEYMONEY5
- UserCramer's Take on Top Search...
- UserPART 4 JPMorgan 27th Annual...
Latest OPTR Headlines from TheStreet
- Optimer Pharmaceuticals Inc. (OPTR): Today's Featured Health Care Winner 11.23.11 | 04:11 pm
- Optimer Stock Gaps Down On Today's Open (OPTR) 11.04.11 | 09:11 am
- 5 Stocks Poised to Pop off Strong Earnings 10.31.11 | 09:10 am
- Biotech Stock Live Chat 10.20.11 | 11:10 am
- Optimer Pharmaceuticals Inc. Stock Downgraded (OPTR) 08.10.11 | 07:08 am
- Optimer Stock Hits New 52-Week Low (OPTR) 08.09.11 | 10:08 am
- Optimer Pharmaceuticals Inc. Stock Downgraded (OPTR) 07.20.11 | 07:07 am
- Optimer Rises On Unusually High Volume (OPTR) 05.31.11 | 11:05 am
- Optimer Prices New Antibiotic at Premium 05.31.11 | 10:05 am
- 5 Stocks to Watch: Intel, Optimer 05.31.11 | 07:05 am
Press Releases for OPTR
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 02.01.12 | 08:02 am
- Chief Operating Officer Tessie M. Che Departing Company - PR Newswire 01.12.12 | 08:01 am
- Optimer Pharmaceuticals Provides Update On DIFICID® (fidaxomicin) Tablets Launch - PR Newswire 01.09.12 | 08:01 am
- Optimer Pharmaceuticals To Present At The 30th Annual J.P. Morgan Healthcare Conference - PR Newswire 01.03.12 | 08:01 am
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 01.03.12 | 08:01 am
- The European Commission Grants Marketing Authorization For DIFICLIR⢠(fidaxomicin) Tablets For Treatment Of Clostridium Difficile Infections - PR Newswire 12.12.11 | 08:12 am
- Data Suggest Optimer's DIFICID® Provides Economic Value In The Treatment Of Clostridium Difficile-associated Diarrhea - PR Newswire 12.06.11 | 08:12 am
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 12.01.11 | 08:12 am
- Optimer Pharmaceuticals To Present At Oppenheimer's 22nd Annual Healthcare Conference - PR Newswire 12.01.11 | 08:12 am
- Optimer Pharmaceuticals To Webcast Investor And Analyst Reception On December 5th - PR Newswire 11.28.11 | 08:11 am
Partner Headlines for OPTR
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- Cubist's Preliminary Sales Impress - Analyst Blog - Zacks 01.11.12 | 10:01 am
- ViroPharma Seals DuoCort Purchase - Analyst Blog - Zacks 11.16.11 | 10:11 am
- EU Nod for ViroPharma-DuoCort Drug - Analyst Blog - Zacks 11.15.11 | 10:11 am
- 20 Oversold Stocks Deeply Undervalued By Target Price - Seeking Alpha 11.11.11 | 07:11 am
- ViroPharma Going Strong - Analyst Blog - Zacks 10.31.11 | 10:10 am
- Buy And Sell Ideas Based On Wednesday's Big News And Price Decliners - Seeking Alpha 09.29.11 | 08:09 am
- Jefferies Has Buy on Optimer Pharmaceutical - Benzinga 09.19.11 | 01:09 pm
- Bullish on Optimer Pharma - Analyst Blog - Zacks 08.15.11 | 06:08 pm
- Optimer Pharmaceuticals (OPTR) - Bull of the Day - Zacks 08.15.11 | 01:08 am
